

Approach to Value Creation

Main development pipeline

MT-1303 (amiselimod)

Concluded licensing agreement (April 2019)	<ul style="list-style-type: none"> ● MTPC grants Bausch Health Companies exclusive rights to develop and commercialize MT-1303 worldwide, except for Japan and certain other countries in Asia, in all fields, excluding neurology, rheumatology and certain rare dermatology diseases. ● Salix Pharmaceuticals Bausch Health Companies a wholly owned subsidiary of Bausch Health Companies plans to begin global development of MT-1303 with the added indication of ulcerative colitis.
Future MTPC Initiatives	<ul style="list-style-type: none"> ● MTPC will file applications for approval and sales in its territories using clinical data provided by Salix Pharmaceuticals. ● MTPC will conduct global in-house development in disease areas such as neurology and rheumatology.

Items targeted for late-stage development

Item	Target disease	Unmet medical needs ¹	Planned for fiscal 2019
MT-8554	Vasomotor symptoms	Safety issues have been reported with hormone replacement therapy and an effective and safe agent is desired.	Phase 2 study completed Under consultation with FDA for Phase 3 study
MT-3995	Non-alcoholic steatohepatitis (NASH)	A multifaceted disease that may eventually lead to cirrhosis and liver cancer, but no therapeutic agents exist.	PoC ² study results to be obtained in Q2 FY2019
MT-7117 ³	Erythropoietic protoporphyria	Neither standard treatment nor oral drug candidate has been developed in US. The only prevention is to avoid exposure to sunlight.	PoC study results to be obtained in Q3 FY 2019


1. Medical needs for which there are no effective treatments or drugs
2. Acronym for Proof of Concept. Confirmation of the efficacy and safety of new drug candidate substances in humans at the R&D stage
3. Fast track designated by the FDA

Modality and digital changes

We will search for drug discovery targets by analyzing medical needs based on the pathway to treatment (patient journey), from diagnosis of disease to treatment period and on to prognosis. To deliver new pharmaceuticals and medical services with differentiated value as fast as possible, we will acquire new modalities in collaboration with partners and streamline clinical trial design by using AI.

Using modalities

In addition to conventional small molecules and antibodies, we also focus on a wide range of modalities. New modalities rapidly increase satisfaction with partnering.



Using AI

We are streamlining clinical development by combining AI that supports information/data collection with AI that supports clinical trial design.

